Display options
Cite
Attinà G, Romano A, Triarico S, et al. Transdermal buprenorphine for pain management in children. Drugs Context. 2021;10doi: 10.7573/dic.2021-6-1.
Attinà, G., Romano, A., Triarico, S., Mastrangelo, S., Maurizi, P., & Ruggiero, A. (2021). Transdermal buprenorphine for pain management in children. Drugs in context, 10. https://doi.org/10.7573/dic.2021-6-1
Attinà, Giorgio, et al. "Transdermal buprenorphine for pain management in children." Drugs in context vol. 10 (2021). doi: https://doi.org/10.7573/dic.2021-6-1
Attinà G, Romano A, Triarico S, Mastrangelo S, Maurizi P, Ruggiero A. Transdermal buprenorphine for pain management in children. Drugs Context. 2021 Sep 14;10. doi: 10.7573/dic.2021-6-1. eCollection 2021. PMID: 34567202; PMCID: PMC8443125.
Copy Download .nbib Format: NLM
Share it on

Drugs Context. 2021 Sep 14;10. doi: 10.7573/dic.2021-6-1. eCollection 2021.

Transdermal buprenorphine for pain management in children.

Drugs in context

Giorgio Attinà, Alberto Romano, Silvia Triarico, Stefano Mastrangelo, Palma Maurizi, Antonio Ruggiero

Affiliations

  1. Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  2. Università Cattolica Sacro Cuore, Rome, Italy.

PMID: 34567202 PMCID: PMC8443125 DOI: 10.7573/dic.2021-6-1

Abstract

Pain is one of the main symptoms reported by sick children, particularly by those suffering from cancer. Opioids are very useful in controlling this symptom but they are burdened with significant side effects that limit their use in children. Buprenorphine is a strong opioid that, due to its particular pharmacological characteristics, ensures excellent pain relief with fewer side effects than other opioids. The transdermal formulation allows for good pain control associated with optimal compliance by patients and few limitations on daily life. Unfortunately, transdermal buprenorphine use remains off-label for the control of chronic pain in children; therefore, it is desirable that new studies can validate its use in the paediatric population. This review aims to analyse the clinical advantages of transdermal buprenorphine in the paediatric population and the possible side effects registered in daily clinical practice.

Copyright © 2021 Attinà G, Romano A, Triarico S, Mastrangelo S, Maurizi P, Ruggiero A.

Keywords: buprenorphine; children; opioids; pain; transdermal

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE)

References

  1. Ann Transl Med. 2021 Jan;9(2):185 - PubMed
  2. J Neurosci. 2009 Jun 3;29(22):7341-8 - PubMed
  3. Br J Anaesth. 2006 May;96(5):627-32 - PubMed
  4. Int J Clin Pract Suppl. 2003 Feb;(133):9-14; discussion 23-4 - PubMed
  5. Br J Anaesth. 2018 Apr;120(4):668-678 - PubMed
  6. Brain Res. 1997 Jan 2;744(1):41-6 - PubMed
  7. Br J Anaesth. 1988 Jan;60(1):48-55 - PubMed
  8. J Pain Symptom Manage. 2020 Nov;60(5):1055-1058 - PubMed
  9. Adv Drug Deliv Rev. 2014 Jun;73:63-82 - PubMed
  10. Neuroscience. 2006 Jul 7;140(3):929-37 - PubMed
  11. J Pain Symptom Manage. 2007 Nov;34(5):532-8 - PubMed
  12. Support Care Cancer. 2005 Nov;13(11):878-87 - PubMed
  13. Paediatr Anaesth. 2011 Mar;21(3):280-90 - PubMed
  14. Paediatr Drugs. 2009;11(2):129-51 - PubMed
  15. Clin Ther. 2005 Feb;27(2):225-37 - PubMed
  16. PLoS One. 2014 Jul 09;9(7):e101948 - PubMed
  17. Cureus. 2019 Oct 21;11(10):e5954 - PubMed
  18. Br J Anaesth. 2005 Jun;94(6):825-34 - PubMed
  19. Anesth Analg. 2005 Mar;100(3):781-785 - PubMed
  20. J Clin Pharm Ther. 2014 Dec;39(6):577-83 - PubMed
  21. J Clin Endocrinol Metab. 2005 Jan;90(1):203-6 - PubMed
  22. Pediatr Blood Cancer. 2013 Mar;60(3):433-7 - PubMed
  23. Eur J Clin Pharmacol. 2013 Oct;69(10):1739-46 - PubMed
  24. Scand J Pain. 2017 Dec 29;4(3):148-152 - PubMed
  25. Gut. 1986 May;27(5):567-9 - PubMed
  26. Drug Alcohol Depend. 2013 Aug 1;131(3):258-62 - PubMed
  27. Eur J Pain. 2006 Oct;10(7):587-95 - PubMed
  28. J Pharm Pharmacol. 1981 Aug;33(8):500-6 - PubMed
  29. Am J Hosp Palliat Care. 2015 Dec;32(8):881-9 - PubMed
  30. Br J Pharmacol. 1977 Aug;60(4):537-45 - PubMed
  31. J Pain Res. 2018 Mar 15;11:549-559 - PubMed
  32. J Pharmacol Exp Ther. 2001 May;297(2):688-95 - PubMed
  33. Pain. 2004 Jul;110(1-2):385-92 - PubMed
  34. Drugs. 2003;63(19):1999-2010; discussion 2011-2 - PubMed
  35. Anaesthesia. 1990 May;45(5):406-8 - PubMed
  36. Pediatr Blood Cancer. 2009 Jan;52(1):125-7 - PubMed
  37. J Neurosci. 2000 Sep 15;20(18):7074-9 - PubMed
  38. J Pain Res. 2015 Dec 04;8:859-70 - PubMed
  39. Ann N Y Acad Sci. 2012 Feb;1248:124-39 - PubMed
  40. Eur J Clin Pharmacol. 1989;36(2):203-4 - PubMed
  41. Pain Pract. 2010 Sep-Oct;10(5):428-50 - PubMed
  42. Clin Pharmacokinet. 1994 Feb;26(2):121-34 - PubMed
  43. Immunopharmacology. 2000 Jul 20;48(2):145-56 - PubMed
  44. J Int Med Res. 1980;8(2):153-5 - PubMed
  45. Curr Opin Support Palliat Care. 2008 Mar;2(1):14-8 - PubMed
  46. Support Care Cancer. 2009 Jun;17(6):715-8 - PubMed
  47. J Anal Toxicol. 1996 Oct;20(6):369-78 - PubMed
  48. Arch Intern Med. 2005 Jul 25;165(14):1574-80 - PubMed
  49. Cancers (Basel). 2019 Jun 13;11(6): - PubMed
  50. Acta Anaesthesiol Sin. 2003 Dec;41(4):187-96 - PubMed
  51. J Support Oncol. 2012 Nov-Dec;10(6):209-19 - PubMed
  52. J Palliat Med. 2020 Aug;23(8):1094-1097 - PubMed
  53. Paediatr Anaesth. 1995;5(2):101-6 - PubMed
  54. Anesthesiol Clin. 2010 Dec;28(4):601-9 - PubMed

Publication Types